Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAM II: exemestane duration neoadjuvant study and adjuvant ibandronate study in hormone receptor-positive early breast cancer
NL-OMON27856Phase 3Recruiting
- Sponsor
- TEAM II Study Group
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of exemestane and ibandronate in breast cancer, sponsored by TEAM II Study Group. Started Oct 2006; status: recruiting.
02
Drugs
exemestaneibandronate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON27856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27856.